Sarepta Therapeutics Inc. (NASDAQ:SRPT) shares fell 1.1% during trading on Monday . The company traded as low as $22.10 and last traded at $22.37, with a volume of 1,803,961 shares changing hands. The stock had previously closed at $22.62.

A number of research firms have recently issued reports on SRPT. JMP Securities reaffirmed a “sell” rating and set a $10.00 price objective on shares of Sarepta Therapeutics in a report on Friday, June 3rd. Vetr raised shares of Sarepta Therapeutics from a “strong sell” rating to a “hold” rating and set a $11.60 price objective for the company in a report on Wednesday, April 27th. Cowen and Company reaffirmed a “hold” rating on shares of Sarepta Therapeutics in a report on Tuesday, June 7th. Janney Montgomery Scott reaffirmed a “hold” rating on shares of Sarepta Therapeutics in a report on Tuesday, June 7th. Finally, Robert W. Baird reaffirmed a “buy” rating on shares of Sarepta Therapeutics in a report on Sunday, May 8th. Five research analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $24.17.

The stock has a 50-day moving average of $19.18 and a 200 day moving average of $18.73. The stock’s market cap is $978.19 million.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Thursday, May 5th. The company reported ($1.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.30) by $0.15. During the same quarter in the prior year, the business posted ($1.15) earnings per share. Analysts forecast that Sarepta Therapeutics Inc. will post ($4.54) EPS for the current year.

Other large investors have recently added to or reduced their stakes in the company. Jennison Associates LLC raised its stake in Sarepta Therapeutics by 463.6% in the fourth quarter. Jennison Associates LLC now owns 838,629 shares of the company’s stock valued at $32,354,000 after buying an additional 689,831 shares during the period. Kornitzer Capital Management Inc. KS raised its stake in Sarepta Therapeutics by 7.5% in the fourth quarter. Kornitzer Capital Management Inc. KS now owns 139,145 shares of the company’s stock valued at $5,368,000 after buying an additional 9,765 shares during the period. California State Teachers Retirement System raised its stake in Sarepta Therapeutics by 9.7% in the fourth quarter. California State Teachers Retirement System now owns 82,932 shares of the company’s stock valued at $3,200,000 after buying an additional 7,300 shares during the period. Swiss National Bank raised its stake in Sarepta Therapeutics by 5.8% in the fourth quarter. Swiss National Bank now owns 61,700 shares of the company’s stock valued at $2,380,000 after buying an additional 3,400 shares during the period. Finally, Mutual of America Capital Management LLC raised its stake in Sarepta Therapeutics by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 60,108 shares of the company’s stock valued at $2,319,000 after buying an additional 358 shares during the period.

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.